PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Enphase Energy, Inc. (NASDAQ: ENPH) (“Enphase” or the “Company”) on behalf of investors who purchased or otherwise acquired Enphase securities during the period from April 22, 2025 through October 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Enphase securities during the Class Period may, no later than April 20, 2026, seek ...

Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi ...

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, ...

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9 ...

Holds of Over 9,000 ETH-based Cryptocurrencies and Staked 2,600 ETH as of February 23, 2026SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we” or the “Company”), a company engaged in the provision of altcoin mining products, and delivery of Web3 infrastructure services via the strategic acquisition and holding of Ethereum-based cryptocurrencies, and operation of a Proof-of-Stake (“PoS”) cryptocurrency staking platform, today provided an update on its Ethereum (“ETH”) acc ...

Core Insights - Treasure Global Inc. reported significant financial progress in Q2 FY2026, with revenue reaching USD 1.08 million, up from USD 0.30 million in Q2 FY2025, driven by growth in gift-card transactions on the ZCITY platform [9] - The company experienced a net loss of USD 3.11 million, compared to a loss of USD 0.23 million in the same quarter last year, although this was partially offset by favorable fair-value adjustments [9] - Cash and cash equivalents increased to USD 5.45 million from USD 0.24 million as of June 30, 2025, supported by financing activities [9] Financial Highlights - Revenue for Q2 FY2026 was USD 1.08 million, a significant increase from USD 0.30 million in Q2 FY2025 [9] - Net loss was USD 3.11 million, compared to USD 0.23 million in Q2 FY2025 [9] - Loss per share improved to USD (3.47) from USD (11.32) in Q2 FY2025 [9] - Cash and cash equivalents rose to USD 5.45 million from USD 0.24 million as of June 30, 2025 [9] Management Commentary - The CEO highlighted the company's progress in strengthening its financial position and advancing technology initiatives [3] - Emphasis was placed on enhancing digital commerce capabilities and expanding higher-value opportunities within the ecosystem [3] - The company is focused on sustainable growth and scaling operations across Southeast Asia [3] Operational Updates - Treasure Global is enhancing its digital commerce ecosystem, particularly through the ZCITY platform [4] - The company is improving product development processes and operational efficiency while expanding merchant partnerships [5] - These efforts aim to diversify revenue streams and strengthen the company's position in Southeast Asia's digital economy [5] Business Outlook - The company plans to continue developing the OXI Wallet initiative, which supports its long-term fintech strategy [6] - OXI Wallet is expected to expand digital asset capabilities and create new revenue opportunities [6] - The company remains committed to optimizing its business model and enhancing operational efficiency [7]

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has received acceptance from the National Medical Products Administration of China for the New Drug Application of ruxolitinib phosphate cream for treating mild to moderate atopic dermatitis, which is expected to accelerate the marketing approval process [1][4]. Group 1: Product Development and Approval - Ruxolitinib phosphate cream has been approved for marketing by the NMPA for the treatment of vitiligo and is now expanding its indications to atopic dermatitis, marking a significant milestone in its therapeutic applications [2]. - The NDA for ruxolitinib phosphate cream has been included in the Priority Review List, reducing the review timeline from 200 days to 130 days, which is anticipated to expedite the product's availability to patients [4]. Group 2: Clinical Trial Results - The product demonstrated robust efficacy in a Phase III clinical trial, achieving a significantly higher proportion of subjects reaching an Investigator's Global Assessment score of 0 or 1 compared to placebo (63.0% vs 9.2%, P < 0.001) [6]. - For the secondary endpoint, 78.0% of subjects treated with ruxolitinib phosphate cream achieved at least a 75% improvement in the Eczema Area and Severity Index score compared to 15.4% in the placebo group (P < 0.001) [6]. Group 3: Market Potential and Strategic Positioning - Atopic dermatitis affects over 54 million patients in China, with mild to moderate cases accounting for 98% of these, indicating a substantial market opportunity for ruxolitinib phosphate cream [5]. - Dermavon is developing a comprehensive "treatment + care" solution for atopic dermatitis, which includes ruxolitinib phosphate cream and other therapeutic options, enhancing its leadership in dermatology [6][7]. - The acceptance of the NDA for atopic dermatitis is expected to strengthen Dermavon's strategic positioning in skin treatments and create synergies with its existing product portfolio, potentially enhancing market competitiveness [8].

Core Insights - Playboy, Inc. expects Q4 2025 revenues to be between $34.0 million and $35.0 million, showing growth from $33.5 million in Q4 2024 [1][6] - The company anticipates a net income of between $2.5 million and $3.5 million, a significant recovery from a net loss of $12.5 million in Q4 2024 [1][6] - Adjusted EBITDA is projected to be between $6.6 million and $7.0 million, compared to a loss of $0.1 million in Q4 2024 [1][6] Financial Performance - Revenue growth is attributed to the strength of the global licensing business, supported by a joint venture with UTG Brands Management Group in China [3][6] - The expected net income includes approximately $1.2 million in transaction costs related to the China licensing joint venture and $0.9 million in litigation costs [6] - The improvement in adjusted EBITDA reflects successful execution of an asset-light strategy and ongoing cost reduction initiatives [6] Management Commentary - The CEO of Playboy highlighted the significant progress in executing the company's strategic transformation, emphasizing revenue growth and strides towards sustainable profitability [3] - The company is focused on leveraging its iconic brand for sustainable, profitable growth as it enters 2026 [4] - Complete financial results for Q4 and fiscal year 2025 are expected to be reported in March 2026 [4]

Core Insights - Reborn Coffee Inc. has entered into a distribution partnership with Sysco Corporation to enhance its supply chain capabilities and support its franchise expansion strategy across the United States [1][2][5] Group 1: Partnership Details - The partnership with Sysco is aimed at improving supply chain execution and standardizing distribution support for both existing and future franchise operators [2][3] - Reborn Coffee will leverage Sysco's distribution network and service capabilities to enhance fulfillment reliability and streamline purchasing processes [3][4] Group 2: Operational Improvements - The collaboration is expected to provide access to quality assurance resources, food safety protocols, and operational tools, which will help stores execute more consistently [3][4] - The structured framework for product delivery will allow franchise operators to focus more on customer experience and revenue-generating operations [4] Group 3: Company Background - Reborn Coffee is a California-based specialty coffee retailer focused on delivering high-quality, handcrafted coffee experiences and is redefining the coffeehouse model through innovation [7] - Sysco, as the global leader in food distribution, operates 340 distribution centers in over 10 countries and generated sales of more than $78 billion in fiscal year 2024 [5][6]

Core Insights - EVA Live, Inc. has launched Fast Quote Direct™, an AI-powered quoting engine aimed at transforming the online services and lead generation industry [1][2] - The platform is designed to convert high-intent traffic into qualified customers through an automated quoting experience [2][4] Company Overview - EVA Live, Inc. is focused on delivering innovative AI-driven media and digital solutions, aiming for scalable growth and long-term shareholder value [8] Product Features - Fast Quote Direct replaces traditional online forms with a dynamic AI-driven interface that guides users through the quoting process in real time [3] - The platform analyzes user responses instantly, matching consumers with appropriate providers across various service categories, including financial services and insurance [3][5] - It utilizes adaptive AI learning to refine targeting and matching, improving accuracy and reducing issues like fraud and incomplete submissions [5] Market Position - Fast Quote Direct is expected to disrupt the online lead generation industry, which is estimated to be worth between $1.6 billion and $3 billion annually in the U.S. [7] - The platform is anticipated to enhance EVA's role from merely generating traffic to full-cycle customer acquisition [7] Future Plans - Fast Quote Direct is currently in beta testing with select partners and is expected to launch commercially in phases throughout 2026 [6] - The platform will function both as an integrated component of the NeuroServer ecosystem and as a standalone SaaS product [6]